BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

(2021) Martine Piccart et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.

(2021) Evandro de Azambuja et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

(2020) Daniel Eiger et al.   BRITISH JOURNAL OF CANCER

Global longitudinal strain: clinical use and prognostic implications in contemporary practice

(2020) Rachid Abou et al.   HEART

Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.

(2020) Anna van der Voort et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.

(2020) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

(2020) Antoinette R Tan et al.   LANCET ONCOLOGY

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

(2019) Richard Gray et al.   LANCET

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

(2019) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

(2019) Zhimin Shao et al.   JAMA Oncology

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

(2018) Andreas Schneeweiss et al.   EUROPEAN JOURNAL OF CANCER

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

(2018) Mette S van Ramshorst et al.   LANCET ONCOLOGY

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

(2017) David Cameron et al.   LANCET

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

(2016) Luca Gianni et al.   LANCET ONCOLOGY

Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure

(2015) Maja Cikes et al.   EUROPEAN HEART JOURNAL

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

(2014) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

(2013) A. Schneeweiss et al.   ANNALS OF ONCOLOGY

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade

(2013) Antonis Valachis et al.   INTERNATIONAL JOURNAL OF CANCER

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY